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Objective: Many medical procedures undergo rapid evolution and process of care improvements after introduction.
National outcome standards are useful to help physicians, institutions, and other stakeholders evaluate the quality of their
programs and take action when suboptimal outcomes are identified. The purpose of this analysis was to derive
contemporary risk-adjusted stroke rates from a large, contemporary, independently assessed outcome database within 30
days after carotid artery stenting (CAS) in the United States.
Methods: The second phase of carotid ACCULINK/ACCUNET post approval trial to uncover rare events (CAPTURE 2)
is an ongoing prospective, multicenter, clinical trial conducted to assess CAS outcomes in the general practice setting after
device approval for high surgical risk patients (symptomatic with >50% stenosis or asymptomatic with >80% stenosis).
A neurologist examined the patients before the procedure, at 1 day and 30 days after CAS. The primary endpoint was a
composite of death, any stroke, or myocardial infarction (MI) within the periprocedural period. Strokes and neurologic
events suspected to be strokes were adjudicated by an independent clinical events adjudication committee. Logistic
regression analysis including stepwise logistic and multivariable modeling was performed to determine clinical predictors
of periprocedural stroke outcome and generate a parsimonious model that could be used for a clinical standard.
Results: Five thousand two hundred ninety-seven consecutive patients (5297) had CAS performed by 459 physicians at 186
sites before the data cutoff of January 10, 2009. The 30-day rate of stroke was 2.7% (95% confidence interval [CI], 2.3–3.2).
Multivariable predictors of periprocedural stroke included age, symptomatic status, and dwell time of embolic protection
device. A parsimoniousmodelPi1/(1e(3.83 0.51 (symptomatic) 0.31 (age>80) 0.62 (age>80 symptomatic)), including
symptomatic and octogenarian status and the term of the interaction of the two, was established based on consideration of
clinical predictors, clinical interaction, and practicability.
Conclusion: CAS outcomes in patients at high surgical risk have comparable periprocedural outcomes to published
randomized trials of endarterectomy for patients at standard surgical risk. A model is presented for calculating a
contemporary national standard for risk-adjusted stroke rates. Quality improvement measures could be based on relative
performance to this benchmark and could improve overall outcomes for patients undergoing CAS. (J Vasc Surg 2010;
52:576-83.)Landmark trials (North American Symptomatic Ca-
rotid Endarterectomy Trial,1 European Carotid Surgery
Trial,2 Asymptomatic Carotid Atherosclerosis Study3 and
Asymptomatic Carotid Surgery Trial4) have established the
indications for carotid endarterectomy (CEA) in patients
with symptomatic stenosis of 50% or more, and asymptom-
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576atic stenosis of 60% or more. The introduction of protected
carotid artery stenting (CAS) has been applied primarily to
patients at high risk for CEA. Recently, smaller randomized
trials (Carotid and Vertebral Artery Transluminal Angio-
plasty Study,5 Stenting with Angioplasty and Protection
in Patients at High Risk for Endarterectomy,6,7 Stent-
Protected Angioplasty vs Carotid Endarterectomy,8 End-
arterectomy vs Angioplasty,9 International Carotid Stent-
ing Study10) have directly compared CEA to CAS, but only
Stenting with Angioplasty and Protection in Patients at
High Risk for Endarterectomy compared the two therapies
in the subgroup of patients who were high-risk for CEA,
which is the current indication approved by the Food and
Drug Administration for CAS in the United States. Two
larger, definitive landmark trials are underway in theUnited
States to compare CAS and CEA in standard risk patients;
one has reported on 2502 subjects and shows both CAS
and CEA equally safe and effective (Carotid Revasculariza-
tion Endarterectomy vs Stenting Trial11) and one is actively
recruiting patients (ACT I12).
With the introduction of CAS, several medical disci-
plines began participating in the interventional care of
patients with carotid stenosis, and separate competency
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levels of clinical, technical, and radiologic skill sets. Rosen-
field et al13 and Creager et al14 published clinical compe-
tence statements relevant to the general interventional
treatment of peripheral vascular disease and specifically to
carotid stenting and were endorsed by several cardiology
and vascular surgery societies. Similarly, both the quality
improvement guidelines set forth by Barr et al15 along with
training, competency, and credentialing standards by Con-
nors et al16 were endorsed by several neurology and radi-
ology societies. Although there were varied levels of skill set
requirements, both sets of documents stressed the impor-
tance of outcomes assessment and comparison to risk-
adjusted standards. Moreover, the Centers for Medicare
and Medicaid Services have issued a national coverage
decision that requires CAS to be performed in hospitals
where ongoing outcomes assessment is performed every 6
months. Finally, industry partners also have interests in
maintaining high standards in performance of CAS. They
have regulatory requirements to perform postmarket stud-
ies to assess the efficacy of carotid devices in the hands of
physician users who have been trained through their pro-
grams. Therefore, a common goal for all physicians, regu-
lators, payers, manufacturers, institutions, and other stake-
holders is the development of a national standard to
measure outcomes after CAS, including risk adjustment to
avoid discouraging appropriate care in very high-risk pa-
tients. Parsimony is central to the utility of risk adjustment;
the model must use easily identifiable risk predictors and be
simple enough to encourage widespread use by physicians
and institutions. Further, identification of risk predictors
for poor outcomes that are available before intervention
should help individualize patient management, as several
options are available for patients with significant carotid
stenosis, including medical management alone, CEA,
and CAS.
METHODS
CAPTURE 2 is an ongoing, prospective, nonrandom-
ized, multicenter, clinical trial for patients undergoing
CAS. Patient selection criteria for this trial have been pre-
viously published.17 Institutional Review Board oversight
was required at each site. An enrolled patient was defined as
any patient whowas consented and had an RXACCULINKor
an RX ACCUNET placed in the carotid artery, whether or
not the procedure was ultimately successful. Patients un-
derwent a neurologic assessment including a National In-
stitutes of Health Stroke Scale at baseline, 24 hours post-
procedure, and 30 days postprocedure performed by an
independent study neurologist (ie, nonoperator). During
the 30-day follow-up, any occurrence of death, stroke,
myocardial infarction (MI), new neurologic event, and
device-related adverse event was reported. All strokes and
suspected strokes were adjudicated by an independent
Clinical Events Adjudication Committee, which included
at least two neurologists. Death and MI were reported by
sites and no routine electrocardiogram or enzyme surveil-
lance was required. The primary endpoint of this study wasa composite of death, stroke, and MI at 30-days postpro-
cedure. This analysis will focus exclusively on building a
model for stroke prediction.
Patients were identified as symptomatic if they had
experienced a transient ischemic attack, amaurosis fugax, or
stroke in the territory supplied by the target vessel within
180 days before the procedure. Stroke included any acute
neurologic ischemic or hemorrhagic event lasting at least
24 hours in duration with focal signs and symptoms. A
major stroke was defined as a new neurologic deficit with an
increase in the National Institutes of Health Stroke Scale of
more than four points from the preprocedure score com-
pared to the 30-day follow-up visit. Strokes not meeting
this definition were categorized as minor. Strokes affecting
the cerebral hemisphere supplied by the study carotid artery
were classified as ipsilateral.
Patients who underwent multiple procedures within 30
days were counted once, and patients who underwent
multiple procedures more than 30 days apart were counted
each time. This approach was used to provide the most
conservative approach to outcome event rates by reducing
the denominator. A total of 248 patients had 2 procedures,
45 within 30 days, and 203 more than 30 days apart. The
first patient was enrolled on March 9, 2006, and patient
enrollment is ongoing in this trial. This report presents data
on 5297 patients who had a CAS procedure performed by
459 physicians at 186 sites as of January 10, 2009. The
clinical trial government number is NCT00302237.
Statistical analyses. Primary analyses on the subsets of
patients based on age and symptomatic status were per-
formed, as prespecified in the study protocol. All analyses
were based on available data. No missing data were im-
puted. Continuous variables were summarized usingmeans
and SD. Categorical variables were summarized as percent-
ages and Clopper-Pearson 95% confidence intervals (CIs).
Normal approximation was used to compute two-side 95%
CI for the difference between two variables. The Kruskal-
Wallis test was used to compare dwell time across more
multiple values of the dependant variable (calcification or
multiple stents). The Cochran-Armitage Trend Test was
performed to evaluate the relationship between comorbid-
ity burden and stroke rates. Univariate logistic regression
analysis was performed on clinically relevant variables.
Those univariables with a P value  .25 were entered into
multivariable logistic regression stepwise modeling to identify
predictors of periprocedural stroke. The multivariable model
was created using stepwise regression, in which variables were
entered into the model at the 0.25 significance level and
removed at the 0.05 level (from the Wald 2 statistic). The
model can be displayed as Logit (Pi) ln (Pi/1 Pi) (0
1X1, i . . . kXk, i ) leading to the predictive algorithm
Pi 1/(1e
(0  1X1,i . . . kXk,i)), in which Pi is a final
predicted probability of ith individual (i1, 2, . . . n),0 is the
intercept, X1 is the first predictor in the model, 1 is the
coefficient of X1, and 2 is the coefficient of the second
predictorX2, and soon.A single clinically plausible interaction
termwas evaluated and added after obtaining the initialmodel
from the stepwise variable selection process. Hosmer and
rians (
patien
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the final multivariable regression model. The leave-one-out
cross-validation was performed to validate the final model, in
which subjects are sequentially deleted one at a time from the
dataset, and the model is retested with each subject missing
once, until all models have been tested. The final model was
reported with odds ratios, 95% CI, and P values. All statistical
analyses were performed with the SAS software program (ver-
sion 9.1.3, SAS Institute, Cary, NC).
RESULTS
Baseline demographics. The mean age for the analy-
sis cohort was 72.3 years old, with 22% patients being 80
years or older (octogenarian). Male patients comprised
61.7% of the population and 14.3% were symptomatic.
Known risk factors for atherosclerotic disease were com-
Table I. Baseline demographics by age and symptomatic s
80
(n  4131 pts)
Age
Mean  SDa,b 69.0  7.6
Age 80 years
(95% CI)
Gender
Male 61.8%
(95% CI) (60.3%, 63.3%)
Medical history
Symptomatic 14.0%
(95% CI) (13.0%, 15.2%)
Diabetes 38.5%
(95% CI)a (37.0%, 40.0%)
Hypertension 88.9%
(95% CI) (87.9%, 89.9%)
Hypercholesterolemia 89.1%
(95% CI)b (88.1%, 90.1%)
Current tobacco user 27.5%
(95% CI)a,b (26.1%, 28.9%)
CHF 18.0%
(95% CI) (16.8%, 19.2%)
Prior MI 26.8%
(95% CI)a,b (25.4%, 28.2%)
Arrhythmia 19.0%
(95% CI)a (17.8%, 20.2%)
CAD 73.1%
(95% CI)b (71.7%, 74.5%)
COPD 24.2%
(95% CI)a (22.9%, 25.5%)
Renal insufficiency 17.7%
(95% CI)a (16.5%, 18.9%)
Unfavorable anatomy 23.1%
(95% CI)a,b (21.8%, 24.4%)
Contralateral occlusion of ICA 18.1%
(95% CI)a (16.9%, 19.4%)
PVD 46.7%
(95% CI)a,b (45.1%, 48.2%)
Prior CEA 17.8%
(95% CI)a,b (16.6%, 19.0%)
CAD, Coronary artery disease; CEA, carotid endarterectomy; CHF, conges
disease; ICA, internal carotid artery; MI, myocardial infarction; n, number;
aStatistically significant difference between nonoctogenarians and octogena
bStatistically significant difference between symptomatic and asymptomaticmon; 89.2% had hypertension, 88.7% had hypercholester-olemia, 36.5% had diabetes, and 23.1% were current to-
bacco users. Frequencies of cardiac comorbidities that
placed the patients at high surgical risk included coronary
artery disease (73.2%), congestive heart failure (18.3%),
prior MI (26.1%), and arrhythmia (21.0%). Frequencies of
noncardiac risk factors were peripheral vascular disease
(45.6%), pulmonary disease (22.3%), and renal insuffi-
ciency (18.7%). A total of 16.8% of the patients had prior
CEA, 21.8% had unfavorable anatomic conditions for
CEA, and 16.9% had occlusions of the contralateral internal
carotid artery.
Baseline demographics for octogenarians and nonocto-
genarian subsets are shown in Table I and are described in
detail elsewhere.18 Significantly more nonoctogenarians
than octogenarians had conditions such as diabetes melli-
tus, unstable angina, chronic obstructive pulmonary dis-
80 Symptomatic Asymptomatic
 1166 pts) (n  721 pts) (n  4337 pts)
3.9  3.0 71.5  10.5 72.5  9.0
23.3% 21.9%
(20.3%, 26.6%) (20.7%, 23.1%)
61.1% 63.4% 61.4%
.2%, 63.9%) (59.7%, 66.9%) (60.0%, 62.9%)
15.0%
.0%, 17.3%)
29.4% 37.0% 36.6%
.8%, 32.1%) (33.5%, 40.6%) (35.1%, 38.0%)
90.2% 87.6% 89.3%
.3%, 91.8%) (85.0%, 89.9%) (88.4%, 90.2%)
87.1% 82.6% 89.7%
.0%, 89.0%) (79.6%, 85.3%) (88.7%, 90.6%)
7.3% 29.1% 22.2%
.8%, 9.0%) (25.7%, 32.6%) (21.0%, 23.5%)
19.3% 16.0% 18.6%
.0%, 21.7%) (13.4%, 18.9%) (17.5%, 19.8%)
23.5% 20.4% 27.1%
.0%, 26.2%) (17.5%, 23.6%) (25.7%, 28.5%)
28.3% 20.0% 21.0%
.7%, 31.0%) (17.1%, 23.1%) (19.8%, 22.2%)
73.2% 64.9% 74.4%
.5%, 75.8%) (61.2%, 68.4%) (73.0%, 75.7%)
15.6% 21.4% 22.6%
.6%, 17.9%) (18.4%, 24.6%) (21.3%, 23.8%)
22.2% 16.4% 18.8%
.8%, 24.7%) (13.7%, 19.3%) (17.6%, 20.0%)
17.1% 27.9% 20.9%
.0%, 19.4%) (24.7%, 31.3%) (19.7%, 22.1%)
12.7% 15.7% 17.0%
.8%, 14.8%) (13.0%, 18.7%) (15.9%, 18.2%)
41.9% 37.8% 46.6%
.0%, 44.9%) (34.2%, 41.6%) (45.1%, 48.2%)
13.1% 13.9% 17.1%
.2%, 15.2%) (11.4%, 16.6%) (16.0%, 18.3%)
eart failure; CI, confidence interval; COPD, chronic obstructive pulmonary
peripheral vascular disease.
  0.05).
ts (  0.05).tatus
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disease, prior CEA, and more were current tobacco users.
However, significantly more octogenarians than non-
octogenarians had arrhythmias and renal insufficiency. In
general, the nonoctogenarian subgroup had more cardio-
vascular disease (except for cardiac arrhythmia) and meta-
bolic disease at baseline than the octogenarian subgroup.
Symptomatic patients had significantly less hypercholester-
olemia, prior MI, coronary artery disease, peripheral vascu-
lar disease, and prior CEA than asymptomatic patients.
However, symptomatic patients had a higher prevalence of
unfavorable anatomic features and more were current to-
bacco users.
Vessel characteristics. Themean percentage of steno-
sis was 85.7%  8.1% (1SD), and the mean lesion length
was 18.3 mm. Approximately half (54.1%) of the lesions
had mild calcification, 23.1% had heavy calcification, and
22.9% had no calcification. Thrombus was present in 3.1%
of the target lesions. Aortic arch anatomy is classified into
three different types (type I, II, or III) based on the vessel
origins and their relationship to a horizontal line drawn
from the left subclavian origin. Type I arch was present in
42.9% of the treated patients; another 44.8% of patients had
type II arches, and 12.3% had type III arches. Approxi-
mately half of the patients (49.8%) had disease in the aortic
Table II. Vessel characteristics by age and symptomatic st
80 years
(n  4131 pts
M  4178 lesions)
Target lesion stenosis (%)
Mean  SD 85.6  8.2
(95% CI)a,b (85.3, 85.8)
Target lesion length (mm)
Mean  SD (N) 18.3  9.0
(95% CI) (18.1, 18.6)
Target site calcification
None 24.2%
(95% CI)a (22.9%, 25.5%)
Mild 54.1%
(95% CI) (52.5%, 55.6%)
Heavy 21.8%
(95% CI)a (20.5%, 23.0%)
Thrombus present at target site 3.4%
(95% CI)a,b (2.9%, 4.0%)
Aortic arch type
I 46.7%
(95% CI)a,b (45.1%, 48.2%)
II 43.2%
(95% CI)a,b (41.7%, 44.7%)
III 10.1%
(95% CI)a (9.2%, 11.1%)
Aortic arch characteristic
Diseased 46.7%
(95% CI)a,b (45.1%, 48.2%)
Nondiseased 53.3%
(95% CI)a,b (51.8%, 54.9%)
CI, Confidence interval; n, number.
aStatistically significant difference between non- and octogenarians (  0.
bStatistically significant difference between symptomatic and asymptomaticarch.Octogenarians had a significantly higher proportion of
heavily calcified lesions, type II aortic arch, type III aortic
arch, and diseased aortic arch than nonoctogenarians (Ta-
ble II). Symptomatic patients had significantly less aortic
arch disease and target lesion stenosis than asymptomatic
patients. However, symptomatic patients had significantly
more of the unfavorable arch type II and over two times
more thrombus present at the target site than asymptom-
atic patients. In addition, 18% (6 of 33) of symptomatic
patients but none (0 of 98) of the asymptomatic patients
who experienced periprocedural stroke had thrombus
present at the lesion site.
Outcomes. The stroke rate was 2.7%, with 0.8% de-
fined as major and 1.9% as minor. No patient had multiple
strokes. The overall stroke rate for symptomatic patients
(4.6%) was twice that of asymptomatic patients (2.3%), P
.0003. Octogenarians had higher adverse event rates than
their younger counterparts, 3.8% vs 2.4%, respectively, P
.0141.
Predictors for periprocedural stroke and modeling.
Predictors identified through stepwise logistic regression
modeling were age, symptomatic status, and embolic pro-
tection device dwell time (DT), defined as the interval
between filter deployment and retrieval (Table III, and
80 years Symptomatic Asymptomatic
 1166 pts
1171 lesions)
(n  721 pts
M  727 lesions)
(n  4337 pts
M  4381 lesions)
6.2  7.9 83.7  11.3 86.1  7.3
.7, 86.6) (82.9, 84.5) (85.9, 86.3)
7.9  8.2 18.1  9.1 18.2  8.7
.5, 18.4) (17.5, 18.8) (17.9, 18.5)
17.4% 23.7% 22.7%
.2%, 19.7%) (20.6%, 26.9%) (21.5%, 24.0%)
55.8% 54.2% 54.3%
.9%, 58.6%) (50.5%, 57.9%) (52.8%, 55.8%)
26.9% 22.1% 23.0%
.3%, 29.5%) (19.2%, 25.3%) (21.8%, 24.3%)
2.1% 6.3% 2.5%
3%, 3.0%) (4.7%, 8.4%) (2.0%, 3.0%)
28.9% 38.0% 43.6%
.3%, 31.6%) (34.4%, 41.7%) (42.1%, 45.1%)
51.3% 49.7% 44.1%
.4%, 54.2%) (46.0%, 53.5%) (42.6%, 45.6%)
19.8% 12.3% 12.3%
.6%, 22.3%) (10.0%, 15.0%) (11.4%, 13.3%)
60.7% 46.0% 50.2%
.8%, 63.5%) (42.2%, 49.7%) (48.7%, 51.7%)
39.3% 54.0% 49.8%
.5%, 42.2%) (50.3%, 57.8%) (48.3%, 51.3%)
ts (  0.05).atus

(n
M 
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(85
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tified as a risk factor for CEA1,8 and CAS.11,17,19
An interaction factor was added to the initial model,
based on strong evidence of an interaction between age and
symptomatic status, as illustrated by Fig 1. The qualitative
interaction indicates that the effect of age80 on outcome
is modified by the symptomatic status of the patient. After
the age 	 symptomatic interaction term was added, the
multivariable model became Pi 1/(1 e
(4.00  0.46 	
(symptomatic) 0.01	 (DT) 0.25	 (age80) 0.75	 (age80	
symptomatic)), in which “symptomatic” equals 0 (asymptom-
atic) or 1 (symptomatic), “age80” equals either 0 (80)
or 1 (80), and “age 80 	 symptomatic” is the product
of both variables and, therefore, equals either 0 or 1. The
Hosmer and Lemeshow test revealed no evidence of a
difference between the observed and predicted stroke rates
(P  .359), confirming goodness-of-fit of the model.
A preprocedural model (without DT) for prediction of
stroke was subsequently derived as Pi 1/(1 e
(3.83 
0.51 	 (symptomatic)  0.31 	 (age 80)  0.62 	 (age 80 	
symptomatic)). This model uses preprocedural information
Table III. Predictors of stroke 30 days from logistic reg
Logistic regression Variable Ratio fo
Stepwise logistic model INTERCEPT
Symptomatic (yes vs no) (y
EPD dwell time (in minutes) (i
Age 80 (yes vs no) (y
Multivariable model INTERCEPT
Symptomatic (yes vs no) (y
EPD dwell time (in minutes) (i
Age 80 (yes vs no) (y
Age-sym (y
CI, Confidence interval; EPD, embolic protection device.
aCoefficients, standard errors for the coefficients and odds ratios are from e
bP values are from the Wald 2 statistic from the final model.
Fig 1. Interaction between age and symptomatic status on stroke
rate.and considers clinical predictors, clinical interaction, andpracticability. The Hosmer and Lemeshow test showed no
evidence of a difference between the observed and pre-
dicted stroke rates (P  .999), confirming goodness-of-fit
of this model. The leave-one-out cross-validation accuracy,
which is defined as the percentage of individual outcomes
accurately predicted, was 97.4%.
Application of the most parsimonious, or preproce-
dural model. Using this final prediction equation, an es-
timated stroke rate can be calculated for a site with known
proportions of symptomatic and octogenarian (age 80 or
older) patients. In clinical practice, the model-predicted
stroke rate at a given study site can be compared to the
observed stroke rate. Fig 2 illustrates how the outcome
rates can be calculated and compared for two sites using
actual data in CAPTURE 2. The model-predicted stroke
rates for each population (far left box) with known popu-
lation frequencies (second to the left boxes) results in
stroke rates (second to the right boxes) for each of the four
populations (asymptomatic 80 years, asymptomatic 80
years, symptomatic 80 years, and symptomatic 80
years). The expected stroke rate for the site is derived as the
weighted average of fractional rates for each of the four
patient populations. This rate can then be compared to the
observed stroke rate to evaluate site performance. Because
site A had more asymptomatic patients (56.8% asymptom-
atic nonoctogenarians and 6.8% asymptomatic octogenari-
ans), the expected stroke rate is lower (2.9%). Conversely,
because site B had more symptomatic patients (41.5%
symptomatic nonoctogenarians and 9.4% symptomatic oc-
togenarians), the expected stroke rate is higher (3.4%). At
site A, the observed stroke rate of 4.6% was much higher
than the expected stroke rate of 2.9%. In contrast, the
observed stroke rate of 1.9% at site B was much lower than
the expected stroke rate of 3.4%.
Comorbidity burden and stroke relationship. Most
patients had multiple comorbidities, as described previ-
ously. We analyzed the stroke outcome and the number of
comorbid conditions including diabetes, hypertension, hy-
percholesterolemia, current tobacco user, congestive heart
failure, prior MI, arrhythmia, coronary artery disease,
chronic obstructive pulmonary disease, renal insufficiency,
on (n  4517)
ry variables Coefficient (SE)a P valueb Odds ratioa (95% CI)
05
no) 0.72 (0.22) .0013 2.05 (1.32, 3.17)
utes) 0.01 (0.00) .0223 1.01 (1.00, 1.02)
no) 0.45 (0.21) .0299 1.57 (1.04, 2.35)
4.00
no) 0.46 (0.29) .1047 1.59 (0.91, 2.78)
utes) 0.01 (0.00) .0189 1.01 (1.00, 1.019)
no) 0.25 (0.25) .3024 1.29 (0.80, 2.09)
no) 0.75 (0.47) .1097 2.11 (0.85, 5.26)
al model.ressi
r bina
4.
es vs
n min
es vs
es vs
n min
es vs
es vsand peripheral vascular disease. The highest number of
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patient had zero conditions (Fig 3). Analysis using the
Cochran-Armitage Trend Test showed no evidence of an
association between the number of comorbidities and the
periprocedural stroke rates (P  .878). Fig 3, showing
stroke rate as a function of comorbidity number, illustrates
that stroke rates were not impacted by increased comorbid-
ity burden.
DISCUSSION
A parsimonious model is presented using practical risk
predictors for calculating contemporary risk-adjusted
stroke rates for CAS. Using the known proportions of
symptomatic and octogenarian patients, a physician or hos-
pital may calculate their performance and compare to other
American providers. Barr et al15 published outcome thresh-
olds, but these were not based on large numbers of actual
CAS outcomes and the guidelines were voluntary. They
pointed out that their outcomes threshold for corrective
Fig 2. Examples of how a model-expected stroke rate is
from two study sites).
Fig 3. Comorbidity burden and stroke relationship. Error bars
represent 95% CI.action is different from the desirable incidence and meanperformance criteria. Low volume outcomes could be
evaluated using the method of an initial 30 hypothetical
trouble-free patients proposed in Barr et al,15 but this may
permit a programwith poor outcomes to continue for some
time before rates crossed thresholds. By presenting a na-
tional benchmark, stakeholders can also assess multiple
factors, such as the size and maturity of a CAS program,
available local or regional treatment alternatives, and actual
outcomes compared to this national benchmark in making
decisions for remedial actions.
This trial has features that make it useful for CAS
institutional outcomes assessment. The large database is
made up of 5297 patients with CAS procedures performed
within the past 3 years and by CAS operators from different
specialties and practice settings across the United States.
The dataset is contemporary in regard to the CAS practice
and technology. The outcome events were independently
assessed and adjudicated by neurologists who were not
directly involved in the study, and this should be considered
when comparing these rates to less sensitive methods of
stroke assessment in clinical practice. The current analysis
revealed that the trial has achieved periprocedural outcome
rates meeting the American Heart Association guidelines
for carotid stenosis intervention.
The DT has been identified as a risk predictor in trials
that measure it,20 and was a significant factor in this initial
multivariable model. The DT could be reflective of diffi-
cult, tortuous anatomy, or long lesion length that prolongs
the procedure and was found to be correlated with calcifi-
cation (Kruskal-Wallis test; P  .0001) and multiple stents
(P  .0001). Although not statistically significant, the
Kruskal-Wallis statistic value showed trends that DT might
be associated with aortic arch type (P .0797) and throm-
bus present in the lesion site (P .0541). DT could also be
a surrogate for prior CAS experience of the individual
operator up to that case. On the other hand, DT may also
be prolonged in patients who have neurologic symptoms or
stroke due to another primary cause. In summary, DT may
be a strong multivariable risk predictor because it correlates
with multiple possible causative and strongly associated
ed and compared with observed stroke rate (actual dataderivstroke factors. However, because it is not uniformly re-
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September 2010582 Matsumura et alcorded across practices and could be prolonged for a variety
of reasons, DT was eliminated from the final, preproce-
dural, more pragmatic model. In contrast to other studies,
we did not identify lesion length or ulceration as significant
predictors in the multivariate analysis.21
Different “high risks” are pertinent to individualized
medical decision in carotid artery disease including risk for
future stroke on medical therapy, risk for death from other
causes, procedural risk for CEA, and procedural risk for
CAS. Clearly, there are some patients with asymptomatic
disease and limited life expectancy that are unlikely to
benefit from either intervention. Knowledge of the impor-
tant risk predictors of CAS will enable better individual
patient management in the context of the patient’s perspec-
tive.
The number of aggregate baseline comorbidities did
not impact CAS outcome rates, possibly reflecting on the
less invasive nature of this carotid intervention compared
with operative therapy and anesthesia. Medical complica-
tions after CEA were analyzed in the North American
Symptomatic Carotid Endarterectomy Trial and were asso-
ciated with preoperative hypertension and coronary artery
disease by multivariate analysis. In the European Carotid
Surgery Trial, multivariate analysis showed that risk factors
for stroke and death after CEA were presentation with
transient ischemic attack, female gender, systolic hyperten-
sion, and peripheral vascular disease.22,23 In prior CAS
trials, octogenarian patient subsets had three to four times
the stroke risk compared to younger patients.11,24 Modern
results in this trial show a less impressive elevation of stroke
risk with CAS in elderly patients. The improved results
overall and in octogenarians, along with observed dif-
ferences in comorbidity between octogenarian and
nonoctogenarian subsets, together suggest an improved
selection of octogenarian patients and may have been re-
sponsible for better outcomes. Although encouraging, this
does not yet demonstrate that individual risk prediction is
effective enough to make CAS a preferred option, particu-
larly for the asymptomatic octogenarian patient. Octoge-
narians were excluded by the Data Safety Management
Board from Carotid Revascularization Endarterectomy
Versus Stenting Trial lead-in but were included in the
randomized portion of the trial. For the present, it is
apparent that this group is still at higher risk for CAS.
Important in this continually evolving field, CAPTURE 2
outcomes are based on currently available technology, and
future developments may further improve outcomes.25-27
One limitation of this trial is that it only ascertained
30-day outcomes. However, 30-day stroke risk captured
the majority of risk difference between CEA and CAS in
several randomized trials reporting between 2-year and
4-year postprocedural outcomes.7-9 The aim of the current
analysis is to identify the risk factors for stroke outcomes
from a large, independently adjudicated CAS dataset, and
then construct a simple preprocedural predictive model.
This model was based on one of the predominant carotid
stent systems used today and the first to be approved in the
United States. It serves as a benchmark, and newer systemscould use similar modeling to create device-specific thresh-
olds for CAS outcomes. Separate analyses, outside of the
scope of this article, focus on individual site/physician
outcomes with analysis of their associated characteristics
and detailed outcomes for octogenarian patients treated
with CAS.18
CONCLUSIONS
A parsimonious model Pi  1/(1  e
(3.83  0.51 	
(symptomatic) 0.31	 (age80) 0.62	 (age80	 symptomatic)),
is presented for calculating a contemporary national bench-
mark for risk-adjusted stroke rates after CAS with embolic
protection. Individuals and institutions may conduct qual-
ity improvement programs intended to improve overall
health outcomes for patients with significant carotid artery
stenosis based on performance relative to this benchmark.
Professional societies and payers have required such out-
comes assessment.
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September 2010583.e1 Matsumura et alTable IV (online only). Predictors of stroke 30 days
Evaluable subjects without dwell time in univariate model
Variable
Age 
 80 years (yes vs no)
Gender (female vs male)
Symptomatic (yes vs no)
Current tobacco user (yes vs no)
Diabetes (yes vs no)
Hypertension (yes vs no)
Hypercholesterolemia (yes vs no)
Hypercholesterolemia requiring medication - Lipostatin (yes vs no
Renal insufficiency (yes vs no)
Renal failure (yes vs no)
Contralateral occlusion of ICA (yes vs no)
MI within 30 days (yes vs no)
Needs CABG within 30 days (yes vs no)
CHF (yes vs no)
Peripheral vascular disease (yes vs no)
Arrhythmia (yes vs no)
Atrial fibrillation (yes vs no)
Coronary artery disease (yes vs no)
Unstable angina (yes vs no)
Pulmonary (yes vs no)
Unfavorable anatomic condition (yes vs no)
Previous carotid endarterectomy (yes vs no)
Lesion length 
20 mm (yes vs no)
Target lesion stenosis 
 90% (yes vs no)
Target lesion calcification (heavy/mild vs none)
Target lesion calcification (heavy vs mild/none)
Thrombus at site (present vs absent)
CABG, Coronary artery bypass graft; CHF, congestive heart failure; CI, co
aFrom the Wald 2 test.from univariate logistic regression  n  5297.
Coefficient P valuea Odds ratio (95% CI)
0.45 .0148 1.56 (1.09, 2.24)
0.17 .3330 0.84 (0.60, 1.19)
0.73 .0004 2.07 (1.39, 3.10)
0.08 .6911 0.92 (0.61, 1.39)
0.15 .3942 0.86 (0.60, 1.22)
0.05 .8537 1.05 (0.61, 1.81)
0.12 .6310 0.88 (0.54, 1.46)
) 0.04 .8250 0.96 (0.65, 1.41)
0.06 .7767 1.06 (0.70, 1.62)
0.48 .4192 0.62 (0.20, 1.97)
0.14 .5163 1.15 (0.75, 1.78)
0.50 .4914 1.65 (0.40, 6.88)
0.30 .5190 0.74 (0.30, 1.83)
0.09 .6840 1.09 (0.72, 1.66)
0.00 .9862 1.00 (0.72, 1.41)
0.05 .8124 1.05 (0.70, 1.57)
0.44 .0516 1.55 (1.00, 2.40)
0.11 .5450 0.89 (0.62, 1.29)
0.48 .0515 1.62 (1.00, 2.62)
0.13 .5296 0.88 (0.58, 1.32)
0.35 .1230 0.71 (0.45, 1.10)
0.18 .4542 0.84 (0.52, 1.34)
0.11 .5198 1.11 (0.80, 1.55)
0.32 .0587 1.38 (0.99, 1.92)
0.40 .0737 1.50 (0.96, 2.33)
0.11 .5639 1.12 (0.76, 1.64)
0.30 .4747 1.35 (0.59, 3.11)
nfidence interval; ICA, internal carotid artery; MI, myocardial infarction.
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from univariate logistic regression  n  5297. Evaluable
subjects without dwell time in univariate model
Variable Coefficient
P
valuea
Odds ratio
(95% CI)
Arch type (II/III vs I) 0.48 .0081 1.61 (1.13, 2.30)
Arch type (III vs I/II) 0.37 .1059 1.45 (0.92, 2.26)
Arch diseased (yes vs no) 0.19 .2611 1.21 (0.87, 1.68)
Echogenicity - (soft vs
calcified/mixed) 0.13 .5315 0.87 (0.58, 1.33)
Echogenicity - (calcified
vs soft/mixed) 0.45 .2217 0.64 (0.31, 1.31)
Anticoagulant usage (yes
vs no) 0.63 .5413 0.53 (0.07, 4.01)
Bivalirudin (yes vs no) 0.32 .1120 0.73 (0.49, 1.08)
Predilatation without
EPD (yes vs no) 0.66 .2586 0.51 (0.16, 1.63)
Poststent dilatation (yes
vs no) 0.12 .8441 1.13 (0.34, 3.81)
Multiple stents used per
side per procedure
(yes vs no) 0.71 .0092 2.03 (1.19, 3.46)
Target lesion side (left vs
right) 0.01 .9512 1.01 (0.73, 1.41)CI, Confidence interval; EPD, embolic protection device.
aFrom the Wald Chi-Square test.
